(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 26.05% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Grail's revenue in 2026 is $147,172,000.On average, 8 Wall Street analysts forecast GRAL's revenue for 2026 to be $7,184,423,699, with the lowest GRAL revenue forecast at $6,570,843,509, and the highest GRAL revenue forecast at $7,572,296,818. On average, 8 Wall Street analysts forecast GRAL's revenue for 2027 to be $9,029,452,313, with the lowest GRAL revenue forecast at $7,969,135,848, and the highest GRAL revenue forecast at $10,196,190,248.
In 2028, GRAL is forecast to generate $11,613,973,698 in revenue, with the lowest revenue forecast at $9,436,816,544 and the highest revenue forecast at $13,740,843,785.